Targeting Continued Androgen Receptor Signaling in Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Targeting continued androgen receptor signaling in prostate cancer.
Prostate cancer is the most common cancer and the second leading cause of death from cancer in males in most Western countries. Prostate cancer has an exquisite sensitivity to androgen deprivation therapy and is the most endocrine-sensitive solid neoplasm, although advanced disease eventually progresses to castration-resistant prostate cancer (CRPC). Recent evidence has shown that cancer progre...
متن کاملAndrogen receptor signaling in androgen-refractory prostate cancer.
Prostate cancer is the second most prevalent cancer in males in the United States. Standard therapy relies on removing, or blocking the actions of, androgens. In most cases, this therapy results in a regression of the cancer because the prostate and most primary prostate tumors depend on androgens for growth and the avoidance of apoptosis. However, a portion of the cancers eventually relapse, a...
متن کاملTargeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280-2. ...
متن کاملAndrogen Signaling in Prostate Cancer.
The androgen-signaling axis plays a pivotal role in the pathogenesis of prostate cancer. Since the landmark discovery by Huggins and Hodges, gonadal depletion of androgens has remained a mainstay of therapy for advanced disease. However, progression to castration-resistant prostate cancer (CRPC) typically follows and is largely the result of restored androgen signaling. Efforts to understand th...
متن کاملCCR New Strategies New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Recent data report that abiraterone acetate, a specific inhibitor of CYP17 that is key to androgen and estrogen synthesis, improves survival in metastatic castration-resistant prostate cancer (CRPC), confirming the continued dependency of CRPC on the androgen receptor (AR) signaling pathway.MDV3100 is a novel antagonist of AR that is also in phase III clinical trials. In addition, several other...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2011
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-10-2815